Mike Rosenbluth, CEO, Swing Therapeutics

Mike founded Swing Therapeutics in 2019. He has been dedicated throughout his career to translating innovation in healthcare with a focus on delivering better care for underserved diseases. He spent his early career at McKinsey & Company where he advised management teams of world-leading health technology and pharmaceutical companies. Mike then invested in innovation-driven healthcare companies at Versant Ventures where he was involved in investments in several notable companies including Inari Medical (IPO, Market Cap $3.5B) and CRISPR Therapeutics (IPO, Market Cap $5B). Before starting Swing, Mike launched two breakthrough genomic-based respiratory products and led business development and strategy at Veracyte. Mike holds a Doctorate Degree in biomedical engineering from UC Berkeley and UCSF and a BS and MS degree in mechanical engineering from Stanford, where he was also a Mayfield Fellow.